{"id":"broad-area-ala-1-hour-incubation","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin irritation"}]},"_chembl":{"chemblId":"CHEMBL263781","moleculeType":"Protein","molecularWeight":"1410.61"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism is based on the principle that abnormal cells, such as those found in actinic keratoses, have a higher rate of porphyrin synthesis than normal cells. The ALA is applied topically and is absorbed by the abnormal cells, where it is converted into porphyrins. These porphyrins then accumulate in the cells and become fluorescent under blue light, allowing for selective destruction of the abnormal cells with a light source.","oneSentence":"ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:52.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"}]},"trialDetails":[{"nctId":"NCT01475955","phase":"PHASE2","title":"Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2011-12","conditions":"Actinic Keratosis","enrollment":235}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Levulan"],"phase":"phase_2","status":"active","brandName":"Broad Area ALA 1-hour incubation","genericName":"Broad Area ALA 1-hour incubation","companyName":"DUSA Pharmaceuticals, Inc.","companyId":"dusa-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy. Used for Actinic keratosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}